Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | HTR2C | P28335 | 3/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HTR5A | P47898 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metitepine SCHEMBL113526 | 1.00 | HTR7 (1.00) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL14359602 | 1.00 | HTR7 (1.00) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL29496251 | 1.00 | HTR7 (1.00) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL8169076 | 0.94 | HTR7 (0.89) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL466985 | 0.92 | MAPT (1.00) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL31360614 | 0.92 | MAPT (1.00) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL15475310 | 0.91 | MAPT (1.00) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| Metitepine SCHEMBL2048660 | 0.91 | MAPT (1.00) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL8877190 | 0.88 | MAPT (0.79) | HTR7MAPTTP53CYP3A4SMN1; SMN2 | |
| SCHEMBL11876604 | 0.87 | HTR7 (0.77) | HTR7MAPTTP53CYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240115564-A1 | HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | disclosed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2022155152-A1 | HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-21 | — | — | WO | disclosed |
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigacions Cientificas (CSIS) (ES) | 2020-12-24 | — | — | US | disclosed |
| EP-3713568-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | Consejo Superior de Investigaciones Cientificas (CSIC) (ES) | 2020-09-30 | — | — | EP | disclosed |
| US-20020182594-A1 | Chemomagnetic retrieval of CMV and CMV infected cells | CHEMOCENTRYX (US) | 2002-12-05 | — | — | US | disclosed |
| US-20020127544-A1 | Modulators of US 28 | CHEMOCENTRYX | 2002-09-12 | — | — | US | disclosed |
| WO-2002062956-A2 | CHEMOMAGNETIC RETRIEVAL OF CMV AND CMV INFECTED CELLS | CHEMOCENTRYX, INC. (US) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002017900-A2 | MODULATORS OF US28 (CHEMOKINES) FOR TREATING CYTOMEGALOVIRUS INFECTIONS | CHEMOCENTRYX, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397752-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR7 11/4885MAPT 322/4885TP53 4651/4885 |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR7 12/4885MAPT 300/4885TP53 4645/4885 |
| US-20240115564-A1 | HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION | HTR1F, HTR1D, HTR1E | HTR7 16/4885MAPT 4647/4885TP53 3093/4885 |
| US-20020127544-A1 | Modulators of US 28 | CCR8, CCL5, CXCL10 | HTR7 2029/4885MAPT 4038/4885TP53 590/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | HTR7 11/4885MAPT 322/4885TP53 4651/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | HTR7 11/4885MAPT 322/4885TP53 4651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.